U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H29FN6O4
Molecular Weight 484.5233
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of BMS-644950

SMILES

CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(=NC(=N1)N(C)C2=NC=NN2C)C3=CC=C(F)C=C3

InChI

InChIKey=QAMJBKXUQQOLPQ-AQRBRUGDSA-N
InChI=1S/C24H29FN6O4/c1-14(2)21-19(10-9-17(32)11-18(33)12-20(34)35)22(15-5-7-16(25)8-6-15)29-23(28-21)30(3)24-26-13-27-31(24)4/h5-10,13-14,17-18,32-33H,11-12H2,1-4H3,(H,34,35)/b10-9+/t17-,18-/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H29FN6O4
Molecular Weight 484.5233
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Approval Year

Patents
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:32:26 UTC 2023
Edited
by admin
on Sat Dec 16 11:32:26 UTC 2023
Record UNII
ZBX3PZ7A0F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-644950
Common Name English
(E,3R,5S)-7-(4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(METHYL-(2-METHYL-1,2,4-TRIAZOL-3-YL)AMINO)PYRIMIDIN-5-YL)-3,5-DIHYDROXY-HEPT-6-ENOIC ACID
Systematic Name English
6-HEPTENOIC ACID, 7-(4-(4-FLUOROPHENYL)-6-(1-METHYLETHYL)-2-(METHYL(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)AMINO)-5-PYRIMIDINYL)-3,5-DIHYDROXY-, (3R,5S,6E)-
Systematic Name English
Code System Code Type Description
CAS
849470-12-8
Created by admin on Sat Dec 16 11:32:26 UTC 2023 , Edited by admin on Sat Dec 16 11:32:26 UTC 2023
PRIMARY
FDA UNII
ZBX3PZ7A0F
Created by admin on Sat Dec 16 11:32:26 UTC 2023 , Edited by admin on Sat Dec 16 11:32:26 UTC 2023
PRIMARY
PUBCHEM
24809501
Created by admin on Sat Dec 16 11:32:26 UTC 2023 , Edited by admin on Sat Dec 16 11:32:26 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
BMS-644950: Rat HMG CoA Reductase= 1.4 nM Rat Hepatocyte IC50 = 395 nM Rat Myocyte IC50 = 995 NM Rat ED50 = 0.11 mpk (myotoxicity window >455x) Guinea Pig ED50 =28 mpk (no CK elevation) Thus, an inhibitor with increased selectivity for hepatocytes could potentially result in an improved therapeutic window. Implementation of a strategy that focused on in vitro potency, compound polarity, cell selectivity, and oral absorption, followed by extensive efficacy and safety modeling in guinea pig and rat, resulted in the identification of compound 1b (BMS-644950).